English

• 

• 1. [1] (a) J. Zhu, H. Bienayme, Multicomponent Reactions, Wiley-VCH, Weinheim, 2005; (b) H. Bienayme, C. Hulme, G. Oddon, P. Schmitt, Maximizing synthetic efficiency: multi-component transformations lead the way, Chem. Eur. J. 6 (2000) 3321-3329; (c) A. Dömling, I. Ugi, Multicomponent reactions with isocyanides, Angew. Chem. Int. Ed. 39 (2000) 3168-3210.[1] (a) J. Zhu, H. Bienayme, Multicomponent Reactions, Wiley-VCH, Weinheim, 2005; (b) H. Bienayme, C. Hulme, G. Oddon, P. Schmitt, Maximizing synthetic efficiency: multi-component transformations lead the way, Chem. Eur. J. 6 (2000) 3321-3329; (c) A. Dömling, I. Ugi, Multicomponent reactions with isocyanides, Angew. Chem. Int. Ed. 39 (2000) 3168-3210.

  2. [2] Z. Huang, Y. Hu, Y. Zhou, D. Shi, Efficient one-pot three-component synthesis of fused pyridine derivatives in ionic liquid, ACS Comb. Sci. 13 (2011) 45-49.[2] Z. Huang, Y. Hu, Y. Zhou, D. Shi, Efficient one-pot three-component synthesis of fused pyridine derivatives in ionic liquid, ACS Comb. Sci. 13 (2011) 45-49.

  3. [3] H. Koga, A. Itoh, S. Murayama, S. Suzue, T. Irikura, The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vivo, J. Med. Chem. 23 (198') 1358-1365.[3] H. Koga, A. Itoh, S. Murayama, S. Suzue, T. Irikura, The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vivo, J. Med. Chem. 23 (198') 1358-1365.

  4. [4] D.C. Hooper, J.C. Wifson, The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans, Antimicrob. Agents Chemother. 28 (1985) 716-721.[4] D.C. Hooper, J.C. Wifson, The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans, Antimicrob. Agents Chemother. 28 (1985) 716-721.

  5. [5] P.C. Sharma, A. Jain, S. Jain, R. Pahwa, M.S.J. Yar, Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects, Enzyme Inhib. Med. Chem. 25 (2009) 577-583.[5] P.C. Sharma, A. Jain, S. Jain, R. Pahwa, M.S.J. Yar, Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects, Enzyme Inhib. Med. Chem. 25 (2009) 577-583.

  6. [6] M.L. Liu, H.Y. Guo, Evolution of the quinolones antibacterial agents, Yakushigaku Zasshi 27 (2006) 69-76.[6] M.L. Liu, H.Y. Guo, Evolution of the quinolones antibacterial agents, Yakushigaku Zasshi 27 (2006) 69-76.

  7. [7] (a) J.A. Makawana, M.P. Patel, R.G. Patel, Synthesis and in vitro antimicrobial activity of N-arylquinoline derivatives bearing 2-morpholinoquinoline moiety, Chin. Chem. Lett. 23 (2012) 427-430; (b) H.G. Kathrotiya, M.P. Patel, Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents, Eur. J. Med. Chem. 63 (2013) 675-684.[7] (a) J.A. Makawana, M.P. Patel, R.G. Patel, Synthesis and in vitro antimicrobial activity of N-arylquinoline derivatives bearing 2-morpholinoquinoline moiety, Chin. Chem. Lett. 23 (2012) 427-430; (b) H.G. Kathrotiya, M.P. Patel, Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents, Eur. J. Med. Chem. 63 (2013) 675-684.

  8. [8] (a) H.G. Kathrotiya, N.A. Patel, R.G. Patel, M.P. Patel, An efficient synthesis of quinolinyl substituted imidazole-5-one derivatives catalyzed by zeolite and their antimicrobial activity, Chin. Chem. Lett. 23 (2012) 273-276; (b) D.C. Mungra, M.P. Patel, D.P. Rajani, R.G. Patel, Synthesis and ide ntification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimic robial and antituberculosis agents, Eur. J. Med. Chem. 46 (2011) 4192-4200.[8] (a) H.G. Kathrotiya, N.A. Patel, R.G. Patel, M.P. Patel, An efficient synthesis of quinolinyl substituted imidazole-5-one derivatives catalyzed by zeolite and their antimicrobial activity, Chin. Chem. Lett. 23 (2012) 273-276; (b) D.C. Mungra, M.P. Patel, D.P. Rajani, R.G. Patel, Synthesis and ide ntification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimic robial and antituberculosis agents, Eur. J. Med. Chem. 46 (2011) 4192-4200.

  9. [9] N.M. Shah, M.P. Patel, R.G. Patel, New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation, Eur. J. Med. Chem. 54 (2012) 239-247.[9] N.M. Shah, M.P. Patel, R.G. Patel, New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation, Eur. J. Med. Chem. 54 (2012) 239-247.

  10. [10] H.H. Jardosh, M.P. Patel, Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents, Eur. J. Med. Chem. 65 (2013) 348-359.[10] H.H. Jardosh, M.P. Patel, Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents, Eur. J. Med. Chem. 65 (2013) 348-359.

  11. [11] J.A. Makawana, D.C. Mungra, M.P. Patel, R.G. Patel, Microwave assisted synthesis and antimicrobial evaluation of new fused pyran derivatives bearing 2-morpholinoquinoline nucleus, Bioorg. Med. Chem. Lett. 21 (2011) 6166-6169.[11] J.A. Makawana, D.C. Mungra, M.P. Patel, R.G. Patel, Microwave assisted synthesis and antimicrobial evaluation of new fused pyran derivatives bearing 2-morpholinoquinoline nucleus, Bioorg. Med. Chem. Lett. 21 (2011) 6166-6169.

  12. [12] (a) W.D. Wilson, M. Zhao, S.E. Patterson, et al., Design of RNA interactive anti-HIV agents: unfused aromatic intercalators, Med. Chem. Res. 2 (1992) 102-110; (b) J.X. Wang, Q. Guo, Y. Chai, et al., Synthesis and in vitro antibacterial activities of 7-(4-alkoxyimino-3-hydroxypiperdin-1-yl)quinolone derivatives, Chin. Chem. Lett. 21 (2010) 55-58.[12] (a) W.D. Wilson, M. Zhao, S.E. Patterson, et al., Design of RNA interactive anti-HIV agents: unfused aromatic intercalators, Med. Chem. Res. 2 (1992) 102-110; (b) J.X. Wang, Q. Guo, Y. Chai, et al., Synthesis and in vitro antibacterial activities of 7-(4-alkoxyimino-3-hydroxypiperdin-1-yl)quinolone derivatives, Chin. Chem. Lett. 21 (2010) 55-58.

  13. [13] P.A. Leatham, H.A. Bird, V. Wright, D. Seymour, A. Gordon, A double blind study of antrafenine, naproxen and placebo in osteoarthrosis, Eur. J. Rheumatol. Inflamm. 6 (1983) 209-211.[13] P.A. Leatham, H.A. Bird, V. Wright, D. Seymour, A. Gordon, A double blind study of antrafenine, naproxen and placebo in osteoarthrosis, Eur. J. Rheumatol. Inflamm. 6 (1983) 209-211.

  14. [14] L. Strekowski, J.L. Mokrosz, V.A. Honkan, et al., Synthesis and quantitative structure-activity relationship analysis of 2-(aryl or heteroaryl)quinolin-4-amines, a new class of anti-HIV-1 agents, J. Med. Chem. 34 (1991) 1739-1746.[14] L. Strekowski, J.L. Mokrosz, V.A. Honkan, et al., Synthesis and quantitative structure-activity relationship analysis of 2-(aryl or heteroaryl)quinolin-4-amines, a new class of anti-HIV-1 agents, J. Med. Chem. 34 (1991) 1739-1746.

  15. [15] W.A. Denny, W.R. Wilson, D.C. Ware, et al., U.S. Patent 7,064,117 (2006).[15] W.A. Denny, W.R. Wilson, D.C. Ware, et al., U.S. Patent 7,064,117 (2006).

  16. [16] (a) K. Muller, C. Faeh, F. Diederich, Fluorine in pharmaceuticals: looking beyond intuition, Science 317 (2007) 1881-1886; (b) S. Purser, P.R. Moore, S. Swallow, V. Gouverneur, Fluorine in medicinal chemistry, Chem. Soc. Rev. 37 (2008) 320-330.[16] (a) K. Muller, C. Faeh, F. Diederich, Fluorine in pharmaceuticals: looking beyond intuition, Science 317 (2007) 1881-1886; (b) S. Purser, P.R. Moore, S. Swallow, V. Gouverneur, Fluorine in medicinal chemistry, Chem. Soc. Rev. 37 (2008) 320-330.

  17. [17] T. Nagai, G. Nishioka, M. Koyama, et al., Reactions of trifluoromethyl ketones. IX. Investigation of the steric effect of a trifluoromethyl group based on the stereochemistry on the dehydration of trifluoromethyl homoallyl alcohols, J. Fluorine Chem. 57 (1992) 229-234.[17] T. Nagai, G. Nishioka, M. Koyama, et al., Reactions of trifluoromethyl ketones. IX. Investigation of the steric effect of a trifluoromethyl group based on the stereochemistry on the dehydration of trifluoromethyl homoallyl alcohols, J. Fluorine Chem. 57 (1992) 229-234.

  18. [18] K.J. Palmer, S.M. Holliday, R.N. Brogden, Mefloquine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy, Drugs 45 (1993) 430-475.[18] K.J. Palmer, S.M. Holliday, R.N. Brogden, Mefloquine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy, Drugs 45 (1993) 430-475.

  19. [19] (a) J.P. Rocher, B. Bonnet, C. Bolea, et al., mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents, Curr. Top. Med. Chem. 11 (2011) 680-695; (b) A.L. Rodriguez, M.D. Grier, C.K. Jones, et al., Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity, Mol. Pharmacol. 78 (2010) 1105-1123.[19] (a) J.P. Rocher, B. Bonnet, C. Bolea, et al., mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents, Curr. Top. Med. Chem. 11 (2011) 680-695; (b) A.L. Rodriguez, M.D. Grier, C.K. Jones, et al., Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity, Mol. Pharmacol. 78 (2010) 1105-1123.

  20. [20] O. Meth-Cohn, N.A. Bramha, A versatile new synthesis of quinolines, thienopyridine and related fused pyridines, Tetrahedron Lett. 23 (1978) 2045-2048.[20] O. Meth-Cohn, N.A. Bramha, A versatile new synthesis of quinolines, thienopyridine and related fused pyridines, Tetrahedron Lett. 23 (1978) 2045-2048.

  21. [21] National Committee for Clinical Laboratory Standards (NCCLS), 940, West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA. Performance standards for antimicrobial susceptibility testing; Twelfth Informational Supplement (ISBN 1-56238-454-6), M100-S12 M7 (2002).[21] National Committee for Clinical Laboratory Standards (NCCLS), 940, West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA. Performance standards for antimicrobial susceptibility testing; Twelfth Informational Supplement (ISBN 1-56238-454-6), M100-S12 M7 (2002).

•